US FDA requires more cardio data for antidiabetes therapies
This article was originally published in SRA
Executive Summary
New drugs and biologics being developed to treat Type 2 diabetes will now have to undergo additional clinical trials to provide evidence that they do not increase the risk of cardiovascular events (such as heart attacks) to an unacceptable level, according to the US Food and Drug Administration1-3.